New Regulations in Australia to Control E-cigarette Access for Youth

Regulations by 2FIRSTS.ai
Jan.09.2024
New Regulations in Australia to Control E-cigarette Access for Youth
Australia's government recently released new regulations to address loopholes in the current laws on e-cigarette products.

According to a report by Lifehacker on January 9th, the Australian government has recently introduced a series of new regulations. These regulations aim to address existing legal loopholes and prevent easy access by teenagers to highly addictive, heavily flavored, inexpensive, and harmful e-cigarette products available in the market.

 

According to regulations prior to 2024, e-cigarette products imported and sold in Australia were required to be nicotine-free, unless obtained through a pharmacy with a prescription from a qualified healthcare professional. Individual users were also allowed to import nicotine-containing e-cigarettes through a personal importation scheme, provided they had a valid prescription.

 

The e-cigarette industry, which encompasses manufacturers, importers, and retailers, exploits these loopholes by falsely claiming that their products are "nicotine-free".

 

However, the only way to distinguish between e-cigarettes that contain nicotine and those that do not is through laboratory testing. Given the large quantity of imported products, this task is time-consuming and expensive, making it nearly impossible to implement a nicotine/non-nicotine standard.

 

The new regulations will help eliminate confusion and make the rules clearer and easier to enforce. It also addresses the issue of easy accessibility of e-cigarettes, which is the biggest challenge in preventing youth smoking.

 

The new regulations will be implemented in three stages.

 

Import Ban: The first phase of the import ban will be implemented from January 1, 2024, encompassing all disposable and single-use e-cigarettes. These products, which come in various flavors such as fruits, candies, cocktails, and tobacco, are particularly popular among young people. While disposable and single-use e-cigarettes cannot be refilled, they come in various sizes ranging from a few hundred puffs to over ten thousand puffs.

 

Starting from March 1, 2024, all other e-cigarettes, including refillable products, will be prohibited from importing unless the importers hold a license and permit from the Office of Drug Control. These legally imported e-cigarettes can only be sold in pharmacies and can only be purchased by users with a prescription.

 

The individual import scheme for e-cigarettes is set to expire on March 1, 2024, which means all e-cigarette users will be required to obtain their products from pharmacies in Australia. While this initial phase has effectively prevented illegal e-cigarettes from entering the country, it has not addressed the existing high volume of products. Retailers are still permitted to sell their existing "nicotine-free" e-cigarette inventory, although it is widely known that these products often do contain nicotine.

 

Ban on domestic manufacturing and sales: The next phase of the reform, expected to take effect later in 2024, will eliminate retail sales of all types of e-cigarette products, regardless of their claimed nicotine content. This second stage will include a prohibition on the manufacturing, supply, advertising, and commercial possession of e-cigarettes that exceed prescription framework limits.

 

These changes will require amendments to the 1989 Therapeutic Commodities Act, which is expected to be submitted for federal parliamentary review in the autumn of 2024, although the exact date has not yet been determined.

 

Prescription Access: Prescription access for e-cigarettes for therapeutic purposes is also undergoing changes, allowing access to products that meet quality standards. Starting from January 1, 2024, all medical and nursing professionals are now able to prescribe therapeutic e-cigarettes for smoking cessation or nicotine addiction management. It is expected that further modifications to the standards for therapeutic e-cigarettes will be made by March 1, 2024, including restrictions on nicotine content, permitted flavor types, and the adoption of standardized medical-style packaging.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21